Engility Holdings Inc. announced Oct. 27 the company has been awarded a $112 million, five-year, single-award IDIQ contract by the Food and Drug Administration Scientific Computing Board and Office of Information Management and Technology. Engility will deliver services unique to computational science and bioinformatics, which promotes gene-based drug discovery and development.
“With this award, Engility expands on our long-standing partnership with the FDA to further develop their high-performance computing and complex data analysis capabilities,” Engility CEO Lynn Dugle said. “We look forward to supporting the FDA’s mission to make groundbreaking treatments, such as genetics-based medicine, available to all Americans.”
As part of the OIMT contract, the Engility team will provide security, operations and maintenance, and technical support for scientific computing environments and systems. Engility will help FDA build fast, reliable and adaptable high-performance computing architectures that accommodate analyses of complex data sets.